Molecular Cancer Therapeutics Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wightman, J.
Right arrow Articles by Yen, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wightman, J.
Right arrow Articles by Yen, A.
Vol. 1, 493-506, May 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Retinoic Acid-induced Growth Arrest and Differentiation: Retinoic Acid Up-Regulates CD32 (Fc{gamma}RII) Expression, the Ectopic Expression of Which Retards the Cell Cycle 1

Jenifer Wightman, Mark S. Roberson, Thomas J. Lamkin, Susi Varvayanis and Andrew Yen2

Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853

Retinoic acid is known to cause the cell cycle arrest and myeloid differentiation of HL-60 myeloblastic leukemia cells. Evidence suggesting the possible involvement of the Fc{gamma}RII immunoglobulin receptor in mediating retinoic acid-induced growth arrest and differentiation of HL-60 cells is presented. HL-60 cells stably transfected with the {Delta}205 mutant polyoma middle T antigen, a largely debilitated polyoma middle T antigen, are known to undergo accelerated retinoic acid-induced growth arrest and differentiation compared with parental HL-60 cells. {Delta}205 transfected cells were compared with parental HL-60 cells by differential display to identify differentially expressed genes, which are regulated downstream of {Delta}205 and might facilitate cellular response to retinoic acid. Differential display revealed that the Fc{gamma}RII immunoglobulin receptor was differentially expressed. HL-60 cells express Fc{gamma}RIIA but not Fc{gamma}RIIB. In parental HL-60 cells, retinoic acid up-regulated Fc{gamma}RII expression, and Fc{gamma}RII membrane protein expression increased concomitantly with retinoic acid-induced cell cycle arrest and differentiation. Ectopic expression of Fc{gamma}RIIa1 in HL-60 cells retarded cellular progression through all phases of the cell cycle. For HL-60 cells stably transfected with Fc{gamma}RIIa1, onset of retinoic acid-induced growth arrest and differentiation occurred in fewer cell cycles than for parental HL-60 cells. Similar results occurred with 1,25-dihydroxy vitamin D3. Retinoic acid-induced tyrosine phosphorylation of various PAGE-detected protein bands in HL-60 cells was enhanced by cross-linking ectopically expressed Fc{gamma}RIIa1 receptor. The known retinoic acid-induced sustained activation of various mitogen-activated protein kinase signaling molecules, including extracellular signal-regulated kinase 2, src-like kinases, and adapter molecules, may in part reflect induced expression of Fc{gamma}RIIA, which is known to activate a similar ensemble of signaling molecules through its ITAM domain. The data suggest that retinoic acid induces increased Fc{gamma}RIIA expression, which is of functional consequence in eliciting growth arrest and differentiation.




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
S. Moqattash and J. D. Lutton
Leukemia Cells and the Cytokine Network: Therapeutic Prospects
Experimental Biology and Medicine, February 1, 2004; 229(2): 121 - 137.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Shaw, M. Elholm, and N. Noy
Retinoic Acid Is a High Affinity Selective Ligand for the Peroxisome Proliferator-activated Receptor {beta}/{delta}
J. Biol. Chem., October 24, 2003; 278(43): 41589 - 41592.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Manor, E. N. Shmidt, A. Budhu, A. Flesken-Nikitin, M. Zgola, R. Page, A. Yu. Nikitin, and N. Noy
Mammary Carcinoma Suppression by Cellular Retinoic Acid Binding Protein-II
Cancer Res., August 1, 2003; 63(15): 4426 - 4433.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.